Biotech Innovation And Pharma Partnering To Address Neglected Diseases - Partnering For Global Health Forum
This article was originally published in PharmAsia News
Executive Summary
CHICAGO - Startup biotechs, including those appearing in emerging markets, could be a strong source of the innovation needed to address global health problems, and Big Pharma and public-private groups are experimenting with novel funding mechanisms and partnerships to help bring new drugs to the developing world
You may also be interested in...
BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City
SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago
BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City
SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago
Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries
Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries